肠道微生态与非小细胞肺癌发生机制及治疗的研究进展  

Research Progress in Microbita and Mechanism and Treatment of Non-Small Cell Lung Cancer

作　　者：石然 何敬东[1] SHI Ran;HE Jingdong(Department of Internal Medicine-Oncology,Huai′an First Hospital Affiliated to Nanjing Medical University,Huai′an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,江苏淮安223300

出　　处：《医学综述》2020年第18期3626-3631,3637,共7页Medical Recapitulate

摘　　要：肠道微生态是人体最大的微生态系统,与人体多个器官组织紧密相关。有些肠道菌群及其代谢产物可以抑制肺免疫,而有些肠道菌群及其代谢产物却可通过调节呼吸道炎症反应增强肺免疫。肠道微生态失衡主要通过肠-肺轴参与非小细胞肺癌(NSCLC)的发生、发展过程。合理控制并调节肠道微生态不仅可以降低NSCLC的发病率,还可以减少晚期NSCLC患者治疗过程中出现的化疗不良反应大、免疫治疗效果不佳等问题。目前粪菌移植等干预肠道微生态的治疗措施已进入临床试验,在NSCLC的防治中具有广阔的应用前景。As the largest microecosystem of human body,intestinal microecology is closely related to multiple organs and tissues.Some intestinal flora and their metabolites can inhibit lung immunity,while some can regulate respiratory inflammation and enhance lung immunity.The imbalance of intestinal microecological participates in the development of non-small cell lung cancer(NSCLC)mainly through the intestinal-lung axis.Reasonable control and regulation of the intestinal microecology can not only reduce the incidence of NSCLC,but also reduce the adverse effects of chemotherapy and enhance the efficacy of immunotherapy in the treatment of patients with advanced NSCLC.At present,fecal microbiota transplantation intervention in the intestinal microecology has entered clinical trials and shown broad application prospects in the prevention and treatment of NSCLC.

关 键 词：非小细胞肺癌 肠道微生态 肠-肺轴 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]